Registry for CML patients in deep remission after stopping pills
Part of Blood & lymphatic, Cancer clinical trials.
This study keeps records of people with chronic-phase CML who stopped their targeted leukemia pills (TKIs) while in a very deep remission. Researchers want to understand outcomes after stopping treatment and how often remissions are maintained.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have chronic-phase CML (not accelerated or blastic phase)
- You took a TKI medicine, either alone or with other treatments
- You have stopped your TKI pills (for any reason)
- Before stopping, you had a very deep remission (very low BCR-ABL1 levels) confirmed multiple times
- You can and are willing to sign informed consent
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at whether some people with chronic myeloid leukemia (CML) can stop CML pills and still keep the disease under control. It is for people who are newly diagnosed or whose current CML treatment did not work well or caused side effects.
This trial looks at how well children with chronic myeloid leukemia (CML) respond to standard “TKI” tablets when treatment starts. It uses genetic test results from diagnosis (DNA/RNA) to understand which children respond better and why.
This trial is a real-life study that collects information from people living with chronic myeloid leukemia (CML). It may help doctors understand how CML treatments are used in practice and how well they work over time.
This follow-up study looks at people with chronic myeloid leukemia (CML) who have been in deep remission and may be able to stay off treatment. It checks how long remission lasts and how their leukemia tests behave over time.
This trial looks at whether people with chronic-phase CML who tried stopping a prior CML medicine and had to restart can later stop treatment again after a set period using asciminib. It checks whether you can stay in a deep remission (“free remission” without the usual CML tablets).
This study tracks the experiences and health outcomes of people with chronic myeloid leukemia (CML) who are taking approved first or second line tyrosine kinase inhibitor (TKI) medicines. It helps doctors learn how these treatments work in everyday care.
Hear when a new Chronic Myeloid Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.